A proof-of-principle pharmacokinetic, pharmacodynamic, and clinical study with purine nucleoside phosphorylase inhibitor immucillin-H (BCX-1777, forodesine).

No abstract is available for this paper.

• Publication year

  2005

• Venue

  Blood

• Publication date

  2005-12-15

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1182/BLOOD-2005-03-1309PMID 16131572PMCID PMC1895256
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Selective Toxicity of Deoxyguanosine and Arabinosyl Guanine for T-Leukemic Cells

  2005cited by this paper
• Intravenous Forodesine (BCX-1777), a Novel Purine Nucleoside Phosphorylase (PNP) Inhibitor, Demonstrates Clinical Activity in Patients with Refractory Cutaneous T-Cell Lymphoma.

  2004cited by this paper
• Antileukemic Activity and Pharmacodynamics of Intravenous Forodesine (BCX-1777), a Novel Purine Nucleoside Phosphorylase (PNP) Inhibitor, in Phase I/II Trials in Patients with Advanced T-Cell Malignancies.

  2004cited by this paper
• Intravenous Forodesine (BCX-1777), a Novel Purine Nucleoside Phosphorylase (PNP) Inhibitor, Demonstrates Clinical Activity in Phase I/II Studies in Patients with B-Cell Acute Lymphoblastic Leukemia.

  2004cited by this paper
• Intravenous and oral pharmacokinetic study of BCX-1777, a novel purine nucleoside phosphorylase transition-state inhibitor. In vivo effects on blood 2'-deoxyguanosine in primates.

  2003cited by this paper
• Mechanism of inhibition of T-acute lymphoblastic leukemia cells by PNP inhibitor--BCX-1777.

  2003cited by this paper
• Crystal structure of human purine nucleoside phosphorylase complexed with acyclovir.

  2003cited by this paper
• Development of transition state analogues of purine nucleoside phosphorylase as anti-T-cell agents.

  2002cited by this paper
• Purine nucleoside phosphorylase inhibitor BCX-1777 (Immucillin-H)--a novel potent and orally active immunosuppressive agent.

  2001cited by this paper
• Addition of lithiated 9-deazapurine derivatives to a carbohydrate cyclic imine: convergent synthesis of the aza-C-nucleoside immucillins.

  2001cited by this paper
• The Metabolic and Molecular Bases of Inherited Disease

  2001cited by this paper
• Immucillin H, a powerful transition-state analog inhibitor of purine nucleoside phosphorylase, selectively inhibits human T lymphocytes

  2001cited by this paper
• Synthesis and Biological Activity of a Novel Class of Purine Nucleoside Phosphorylase Inhibitors

  2000cited by this paper
• Synthesis of transition state analogue inhibitors for purine nucleoside phosphorylase and N-riboside hydrolases

  2000cited by this paper
• Pharmacokinetics and Pharmacodynamics of Peldesine (BCX‐34), a Purine Nucleoside Phosphorylase Inhibitor, following Single and Multiple Oral Doses in Healthy Volunteers

  2000cited by this paper
• Crystal structure of the purine nucleoside phosphorylase (PNP) from Cellulomonas sp. and its implication for the mechanism of trimeric PNPs.

  1999cited by this paper
• One-third-the-sites transition-state inhibitors for purine nucleoside phosphorylase.

  1998cited by this paper
• Ribonucleotide reductases.

  1998cited by this paper
• Effects of a novel purine nucleoside phosphorylase inhibitor, BCX-34, on activation and proliferation of normal human lymphoid cells.

  1998cited by this paper
• Cellular pharmacodynamics and plasma pharmacokinetics of parenterally infused hydroxyurea during a phase I clinical trial in chronic myelogenous leukemia.

  1998cited by this paper
• The crystal structure of Escherichia coli purine nucleoside phosphorylase: a comparison with the human enzyme reveals a conserved topology.

  1997cited by this paper
• Induction of apoptotic program in cell-free extracts: requirement for dATP and cytochrome c.

  1996cited by this paper
• Bayesian sequential monitoring designs for single-arm clinical trials with multiple outcomes.

  1995cited by this paper
• Pre-steady-state transition-state analysis of the hydrolytic reaction catalyzed by purine nucleoside phosphorylase.

  1995cited by this paper
• Purine nucleoside phosphorylase inhibitors: biochemical and pharmacological studies with 9-benzyl-9-deazaguanine and related compounds.

  1993cited by this paper
• Purine nucleoside phosphorylase. Catalytic mechanism and transition-state analysis of the arsenolysis reaction.

  1993cited by this paper
• Comparative in vitro and in vivo activities of two 9-deazaguanine analog inhibitors of purine nucleoside phosphorylase, CI-972 and PD 141955.

  1992cited by this paper
• Purine nucleoside phosphorylase deficiency.

  1991cited by this paper
• The Metabolic basis of inherited disease

  1989cited by this paper
• Enzymatic assay for deoxyribonucleoside triphosphates using synthetic oligonucleotides as template primers.

  1989cited by this paper
• Preliminary report on 8-amino-9-(2-thienylmethyl)guanine (PD 119,229), a novel and potent purine nucleoside phosphorylase inhibitor

  1987cited by this paper
• Central nervous system dysfunction and erythrocyte guanosine triphosphate depletion in purine nucleoside phosphorylase deficiency.

  1987cited by this paper
• The metabolism of deoxyguanosine in mitochondria: a characterization of the phosphorylation process which occurs in intact mitochondria.

  1987cited by this paper
• Phosphorylation of deoxyguanosine in intact and fractured mitochondria

  1987cited by this paper
• Mechanisms of deoxyguanosine toxicity for human T and B lymphocytes.

  1986cited by this paper
• Purine Nucleoside Phosphorylase

  1985cited by this paper
• Selective toxicity of deoxyguanosine and arabinosyl guanine for T-leukemic cells.

  1983cited by this paper
• Inhibition of purine nucleoside phosphorylase by 8-aminoguanosine: selective toxicity for T lymphoblasts.

  1981cited by this paper
• Biochemistry of diseases of immunodevelopment.

  1981cited by this paper
• Quantitation of 1-beta-D-arabinofuranosylcytosine 5'-triphosphate in the leukemic cells from bone marrow and peripheral blood of patients receiving 1-beta-D-arabinofuranosylcytosine therapy.

  1980cited by this paper
• Biochemical basis for the enhanced toxicity of deoxyribonucleosides toward malignant human T cell lines.

  1979cited by this paper
• Partial purification and characterization of deoxyguanosine kinase from pig skin.

  1979cited by this paper
• Purinogenic immunodeficiency diseases: selective toxicity of deoxyribonucleosides for T cells.

  1978cited by this paper
• Purine nucleoside phosphorylase deficiency associated with selective cellular immunodeficiency.

  1977cited by this paper
• Lymphospecific toxicity in adenosine deaminase deficiency and purine nucleoside phosphorylase deficiency: possible role of nucleoside kinase(s).

  1977cited by this paper
• Abnormal purine metabolism and purine overproduction in a patient deficient in purine nucleoside phosphorylase.

  1976cited by this paper
• Nucleoside-phosphorylase deficiency in a child with severely defective T-cell immunity and normal B-cell immunity.

  1975cited by this paper
• Purine nucleoside phosphorylase from human erythrocytes. I. Purification and properties.

  1968cited by this paper
• Inhibition of human purine nucleoside phosphorylase. Studies with intact erythrocytes and the purified enzyme.

  1968cited by this paper
• Purine nucleoside phosphorylase: kinetics, mechanism, and specificity.

  1967cited by this paper

• Nucleotide salvage, genome instability, and potential therapeutic applications

  2026cites this paper
• Metabolic constraint of human telomere length by nucleotide salvage efficiency

  2025cites this paper
• Fueling for the finish line: Control of human telomerase activity by nucleotide metabolism.

  2025cites this paper
• Design, Synthesis, Biological Evaluation, and Crystallographic Study of Novel Purine Nucleoside Phosphorylase Inhibitors

  2023cites this paper
• The pathogenesis and development of targeted drugs in acute T lymphoblastic leukaemia

  2023cites this paper
• An expedient approach for the regioselective synthesis of novel 1,5,6,7-tetrahydro-2H-pyrrolo[3,2-d]pyrimidine-2,4(3H,5H)-dione derivatives via Fe (III)-mediated iodocyclization

  2022cites this paper
• Carbohydrate-based drugs launched during 2000−2021

  2022cites this paper
• Targeting nucleotide metabolism: a promising approach to enhance cancer immunotherapy

  2022cites this paper
• Dietary poly‐β‐hydroxybutyrate supplementation can effectively improve growth, digestive enzyme activities, immune‐related gene expression, disease resistance, and intestinal mucosal barrier of gibel carp, Carassius auratus gibelio

  2022cites this paper
• Synthesis of Piperidine Nucleosides as Conformationally Restricted Immucillin Mimics

  2021cites this paper
• SAMHD1 limits the efficacy of forodesine in leukaemia by protecting cells against cytotoxicity of dGTP

  2020cites this paper
• Characterization of the N6-etheno-bridge method to assess extracellular metabolism of adenine nucleotides: detection of a possible role for purine nucleoside phosphorylase in adenosine metabolism

  2020cites this paper
• SAMHD1 Limits the Efficacy of Forodesine in Leukemia by Protecting Cells against the Cytotoxicity of dGTP

  2020cites this paper
• Computer-aided rational design of acyclovir analogs to inhibit purine nucleoside phosphorylase

  2019cites this paper
• Increased dNTP pools rescue mtDNA depletion in human POLG‐deficient fibroblasts

  2019cites this paper
• Novel and Future Therapeutic Drugs for Advanced Mycosis Fungoides and Sézary Syndrome

  2019influential citation
• Deoxyguanosine is a TLR7 agonist

  2019cites this paper
• Biofloc technology (BFT): An alternative aquaculture system for prevention of Cyprinid herpesvirus 2 infection in gibel carp (Carassius auratus gibelio)

  2018cites this paper
• The transition to magic bullets - transition state analogue drug design.

  2018cites this paper
• Enzymatic Transition States and Drug Design.

  2018cites this paper
• Forodesine in the treatment of relapsed/refractory peripheral T-cell lymphoma: an evidence-based review

  2018cites this paper
• In-silico gene essentiality analysis of polyamine biosynthesis reveals APRT as a potential target in cancer

  2017cites this paper
• Cutaneous T-Cell Lymphoma: A Review with a Focus on Targeted Agents

  2016cites this paper
• Treating adults with acute lymphocytic leukemia: new pharmacotherapy options

  2016cites this paper
• Nucleoside analogs: ready to enter the era of precision medicine?

  2016cites this paper
• Differences in Protein Expression between the U251 and U87 Cell Lines.

  2016cites this paper
• Current Management of Adult Acute Lymphoblastic Leukaemia: Emerging Insights and Outstanding Questions

  2016cites this paper
• A β -Fluoroamine Inhibitor of Purine Nucleoside Phosphorylase

  2015cites this paper
• Antimetabolites That Interfere with Nucleic Acid Biosynthesis

  2015cites this paper
• Immucillins ImmA and ImmH Are Effective and Non-toxic in the Treatment of Experimental Visceral Leishmaniasis

  2015cites this paper
• Other Chemotherapeutic Agents in Cutaneous T-Cell Lymphoma.

  2015cites this paper
• Different expression profiles of Interleukin 11 (IL-11), Intelectin (ITLN) and Purine nucleoside phosphorylase 5a (PNP 5a) in crucian carp (Carassius auratus gibelio) in response to Cyprinid herpesvirus 2 and Aeromonas hydrophila.

  2014cites this paper
• Final results of a multicenter phase II study of the purine nucleoside phosphorylase (PNP) inhibitor forodesine in patients with advanced cutaneous T-cell lymphomas (CTCL) (Mycosis fungoides and Sézary syndrome).

  2014cites this paper
• An Efficient Synthesis of 3H‐Pyrrolo[3,2‐d]pyrimidin‐4(5H)‐one Derivatives via an Iminophosphorane

  2014cites this paper
• Efficient and Selective Construction of Pyrrolo(3,2-d)pyrimidine Derivatives

  2014cites this paper
• Emerging drugs for acute lymphocytic leukemia

  2014cites this paper
• Nucleoside Analogs in the Therapy of T-Cell Malignancies

  2013cites this paper
• Preclinical and clinical evaluation of forodesine in pediatric and adult B-cell acute lymphoblastic leukemia.

  2013cites this paper
• Older and new purine nucleoside analogs for patients with acute leukemias.

  2013cites this paper
• Structures of purine nucleosidase from Trypanosoma brucei bound to isozyme-specific trypanocidals and a novel metalorganic inhibitor.

  2013cites this paper
• Resistance to TRAIL in mantle cell lymphoma cells is associated with the decreased expression of purine metabolism enzymes.

  2013influential citation
• Novel Therapies for Pediatric Cancers

  2012cites this paper
• Emerging treatment approaches in acute lymphoblastic and acute myeloid leukemias

  2012cites this paper
• Novel and emerging drugs for acute lymphoblastic leukemia.

  2012cites this paper
• What is the impact, present and future, of novel targeted agents in acute lymphoblastic leukemia?

  2012cites this paper
• Recent Developments in the Management of T-Cell Precursor Acute Lymphoblastic Leukemia/Lymphoma

  2012cites this paper
• Emerging Pharmacotherapies for Adult Patients with Acute Lymphoblastic Leukemia

  2012cites this paper
• Biology of acute lymphoblastic leukemia (ALL): clinical and therapeutic relevance.

  2011cites this paper
• Effects of purine nucleoside phosphorylase deficiency on thymocyte development.

  2011cites this paper
• Pharmacology of Acute Lymphoblastic Leukemia Therapy

  2011cites this paper
• In vitro efficacy of forodesine and nelarabine (ara-G) in pediatric leukemia.

  2011cites this paper
• T-Cell Acute Lymphoblastic Leukemia

  2011cites this paper
• and activates p53-independent mitochondrial apoptosis by induction of Forodesine has high antitumor activity in chronic lymphocytic leukemia

  2011cites this paper
• [Novel conventional therapies in onco-hemathology].

  2011cites this paper
• New Agents for the Treatment of Acute Lymphblastic Leukemia

  2011influential citation
• Treatment of Relapsed Acute Lymphoblastic Leukemia

  2011cites this paper
• Salvage Therapy of Adult Acute Lymphoblastic Leukemia

  2011cites this paper
• An update on the management of peripheral T-cell lymphoma and emerging treatment options

  2011cites this paper
• [Lymphoid malignancies: progress in diagnosis and treatment. Topics: III. Diagnosis and treatment; 5. Developmental status and perspective of new drugs for lymphoid malignancies in Japan].

  2011cites this paper
• Biology and treatment of acute lymphoblastic leukemia.

  2010cites this paper
• Potent orally bioavailable purine nucleoside phosphorylase inhibitor BCX-4208 induces apoptosis in B- and T-lymphocytes--a novel treatment approach for autoimmune diseases, organ transplantation and hematologic malignancies.

  2010cites this paper
• The Effects of Forodesine in Murine and Human Multiple Myeloma Cells

  2010cites this paper
• Influence of bone marrow stromal microenvironment on forodesine-induced responses in CLL primary cells.

  2010cites this paper
• New targets of therapy in T-cell lymphomas.

  2010cites this paper
• Antiproliferative Activity of Purine Nucleoside Phosphorylase Multisubstrate Analogue Inhibitors Containing Difluoromethylene Phosphonic Acid against Leukaemia and Lymphoma Cells

  2010cites this paper
• 皮膚リンパ腫の海外・本邦での治療, 治療ガイドライン

  2010cites this paper
• Phase 2 and pharmacodynamic study of oral forodesine in patients with advanced, fludarabine-treated chronic lymphocytic leukemia.

  2010cites this paper
• Forodesine: review of preclinical and clinical data.

  2010cites this paper
• Novel therapies for peripheral T-cell non-Hodgkin's lymphomas

  2009cites this paper
• Iminosugars: from botanical curiosities to licensed drugs

  2009cites this paper
• Inhibition of ATP synthase by chlorinated adenosine analogue.

  2009cites this paper
• Forodesine has high antitumor activity in chronic lymphocytic leukemia and activates p53-independent mitochondrial apoptosis by induction of p73 and BIM.

  2009cites this paper
• Novel drugs for chronic lymphoid leukemias: mechanism of action and therapeutic activity.

  2009cites this paper
• Current and future aggressive peripheral T-cell lymphoma treatment paradigms, biological features and therapeutic molecular targets.

  2009cites this paper
• New therapeutic strategies in acute lymphoblastic leukemia.

  2009cites this paper
• Phase I trial of nelarabine in indolent leukemias.

  2008cites this paper
• Purine Salvage Pathways in the Intraerythrocytic Malaria Parasite Plasmodium falciparum

  2008cites this paper
• Current developments in the synthesis and biological activity of aza-C-nucleosides: immucillins and related compounds.

  2008cites this paper
• A beta-fluoroamine inhibitor of purine nucleoside phosphorylase.

  2008cites this paper
• New agents for the treatment of patients with acute lymphoblastic leukemia

  2008cites this paper
• Plasmodium falciparum Purine Nucleoside Phosphorylase Is Critical for Viability of Malaria Parasites*

  2008cites this paper
• Experimental therapeutic strategies for thetreatment of atopic dermatitis

  2008cites this paper
• Novel purine nucleoside analogues for hematological malignancies.

  2008cites this paper
• Transition-state analysis of the DNA repair enzyme MutY.

  2008cites this paper
• Chapter 2 – Antimetabolites

  2008cites this paper
• Biology and treatment of acute lymphoblastic leukemia.

  2008cites this paper
• Determinants of sensitivity of human T-cell leukemia CCRF-CEM cells to immucillin-H.

  2008cites this paper
• Cytotoxic nucleoside analogues: different strategies to improve their clinical efficacy.

  2008cites this paper
• Pediatric developmental therapies: Interesting new drugs now in early-stage clinical trials

  2008cites this paper
• Nucleic acids as therapeutic agents.

  2008cites this paper
• Purine Nucleosidase Phosphorylase (PNP): A novel target in leukemias and lymphomas.

  2007cites this paper
• Enzymatic Transition State Theory and Transition State Analogue Design*

  2007cites this paper
• Analysis of PUGNAc and NAG-thiazoline as transition state analogues for human O-GlcNAcase: mechanistic and structural insights into inhibitor selectivity and transition state poise.

  2007cites this paper
• A Transition State Analogue of 5′-Methylthioadenosine Phosphorylase Induces Apoptosis in Head and Neck Cancers*

  2007cites this paper
• C-Functionalization of 9-deazapurines by cross-coupling reactions

  2007cites this paper
• Incorporation of extracellular 8-oxodG into DNA and RNA requires purine nucleoside phosphorylase in MCF-7 cells

  2007cites this paper
• Forodesine (BCX-1777, Immucillin H)--a new purine nucleoside analogue: mechanism of action and potential clinical application.

  2007cites this paper
• New therapeutic strategies for the treatment of acute lymphoblastic leukaemia

  2007cites this paper
• Diagnosis and treatment of childhood non-hodgkin lymphoma.

  2007cites this paper
• Three new drugs for acute lymphoblastic leukemia: nelarabine, clofarabine, and forodesine.

  2007cites this paper